Isoform Positions

Isoform Protein Position Transcript Position Chromosomal Position (HG38) Chromosomal Position (HG19)
IC3234797264;97265;97266 chr2:178542815;178542814;178542813chr2:179407542;179407541;179407540
N2AB3070692341;92342;92343 chr2:178542815;178542814;178542813chr2:179407542;179407541;179407540
N2A2977989560;89561;89562 chr2:178542815;178542814;178542813chr2:179407542;179407541;179407540
N2B2328270069;70070;70071 chr2:178542815;178542814;178542813chr2:179407542;179407541;179407540
Novex-12340770444;70445;70446 chr2:178542815;178542814;178542813chr2:179407542;179407541;179407540
Novex-22347470645;70646;70647 chr2:178542815;178542814;178542813chr2:179407542;179407541;179407540
Novex-3NoneNone chr2:Nonechr2:None

Information

  • RefSeq wild type amino acid: L
  • RefSeq wild type transcript codon: CTG
  • RefSeq wild type template codon: GAC
  • Domain: Ig-154
  • Domain position: 41
  • Structural Position: 58
  • Q(SASA): 0.1965
  • Predicted PPI site: N

Reported SAVs

SNV RS
DUET
PolyPhen-2
Condel
Rhapsody
REVEL
MVP
Source
MAF
Disease
Zygosity
Site annotation
mCSM PPI
Predicted PPI site
Comments
AFR
AMR
AMS
ASJ
EAS
EUR
FIN
MDE
NFE
SAS
OTH
L/V None None 0.17 N 0.377 0.162 0.381580015636 gnomAD-4.0.0 1.20032E-06 None None None None N None 0 0 None 0 0 None 0 0 1.3125E-06 0 0

Saturation Mutagenesis

SAV
AlphaMissense (IC)
AlphaMissense Class (IC)
AlphaMissense (N2AB)
AlphaMissense Class (N2AB)
mCSM
mCSM class
PolyPhen-2
PolyPhen-2 Class
Rhapsody
Rhapsody Class
Condel
Condel Score
Site annotation
mCSM PPI
Predicted PPI site
L/A 0.7906 likely_pathogenic 0.7121 pathogenic -1.926 Destabilizing 0.953 D 0.495 neutral None None None None N
L/C 0.8517 likely_pathogenic 0.7778 pathogenic -1.203 Destabilizing 0.999 D 0.659 neutral None None None None N
L/D 0.9875 likely_pathogenic 0.9803 pathogenic -1.674 Destabilizing 0.998 D 0.781 deleterious None None None None N
L/E 0.9186 likely_pathogenic 0.8817 pathogenic -1.459 Destabilizing 0.998 D 0.765 deleterious None None None None N
L/F 0.4334 ambiguous 0.325 benign -1.122 Destabilizing 0.986 D 0.573 neutral None None None None N
L/G 0.9425 likely_pathogenic 0.9071 pathogenic -2.403 Highly Destabilizing 0.993 D 0.747 deleterious None None None None N
L/H 0.8673 likely_pathogenic 0.7938 pathogenic -1.598 Destabilizing 0.999 D 0.767 deleterious None None None None N
L/I 0.1076 likely_benign 0.1013 benign -0.565 Destabilizing 0.06 N 0.398 neutral None None None None N
L/K 0.8537 likely_pathogenic 0.8054 pathogenic -1.288 Destabilizing 0.993 D 0.712 prob.delet. None None None None N
L/M 0.2014 likely_benign 0.1637 benign -0.587 Destabilizing 0.76 D 0.455 neutral N 0.512544267 None None N
L/N 0.9314 likely_pathogenic 0.9056 pathogenic -1.653 Destabilizing 0.998 D 0.782 deleterious None None None None N
L/P 0.848 likely_pathogenic 0.7854 pathogenic -0.998 Destabilizing 0.997 D 0.781 deleterious D 0.536270836 None None N
L/Q 0.7551 likely_pathogenic 0.651 pathogenic -1.48 Destabilizing 0.991 D 0.744 deleterious D 0.536524326 None None N
L/R 0.8221 likely_pathogenic 0.7404 pathogenic -1.142 Destabilizing 0.991 D 0.744 deleterious D 0.536270836 None None N
L/S 0.9298 likely_pathogenic 0.8868 pathogenic -2.349 Highly Destabilizing 0.993 D 0.69 prob.neutral None None None None N
L/T 0.7982 likely_pathogenic 0.7201 pathogenic -1.978 Destabilizing 0.986 D 0.606 neutral None None None None N
L/V 0.1578 likely_benign 0.1375 benign -0.998 Destabilizing 0.17 N 0.377 neutral N 0.517055516 None None N
L/W 0.7309 likely_pathogenic 0.5978 pathogenic -1.336 Destabilizing 0.999 D 0.715 prob.delet. None None None None N
L/Y 0.8023 likely_pathogenic 0.7037 pathogenic -1.029 Destabilizing 0.998 D 0.697 prob.neutral None None None None N

Titin has multiple isoforms, the longest being the theoretical IC (inferred complete) isoform which contains all 363 in-frame titin exons. Here all isoform positions have been mapped onto the IC sequence, with an exception being the C-terminal of the much shorter novex-3 isoform. This contains the out of frame exon 48 which cannot be mapped to the other isoforms.